Pds biotechnology to present at the hc wainwright 23rd annual global investment conference

Florham park, n.j., sept. 07, 2021 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing novel cancer therapies based on the company's proprietary versamune® t-cell activating technology, announced today that its management will present at the hc wainwright 23rd annual global investment conference.
PDSB Ratings Summary
PDSB Quant Ranking